Homologous boosting with the prototype Novavax COVID-19 vaccine induced robust antibody titers for Omicron BA.1, BA.2, and BA.5
Study 307 (Lot Consistency) achieved its primary endpoint, showing that three vaccine lots induced a comparable immune response thereby demonstrating the consistency of the manufacturing process
A durable immunogenicity response was observed following primary vaccination as well as boosting which matched the levels previously associated with protection
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.